Original Article

Transcriptional regulation of βsecretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments

  1. Jin Chu PhD,
  2. Jia-Min Zhuo PhD†,
  3. Domenico Praticò MD*

Article first published online: 24 JAN 2012

DOI: 10.1002/ana.22625

Issue

Annals of Neurology

Annals of Neurology

Volume 71, Issue 1, pages 57–67, January 2012

Additional Information

How to Cite

Chu, J., Zhuo, J.-M. and Praticò, D. (2012), Transcriptional regulation of βsecretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol., 71: 57–67. doi: 10.1002/ana.22625

Author Information

  1. Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA

  1. †

    Dr Zhuo: Department of Biomedical Engineering, Boston University, Boston, MA, 02115

*Department of Pharmacology, Temple University, 3420 North Broad Street, MRB, 706A, Philadelphia, PA 19140

Publication History

  1. Issue published online: 24 JAN 2012
  2. Article first published online: 24 JAN 2012
  3. Accepted manuscript online: 12 SEP 2011 08:28AM EST
  4. Manuscript Accepted: 2 SEP 2011
  5. Manuscript Revised: 23 AUG 2011
  6. Manuscript Received: 27 JUL 2011

Funded by

  • National Institute of Aging (NIH). Grant Number: AG33568
  • Alzheimer association. Grant Number: NPSP-10-170775

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (993K)

Abstract

Objective:

12/15-Lipoxygenase (12/15-LO) is an enzyme widely distributed in the central nervous system, and it has been involved in the neurobiology of Alzheimer disease (AD). However, the mechanism involved remains elusive.

Methods:

We investigated the molecular mechanism by which 12/15-LO regulates amyloid β (Aβ)/Aβ precursor protein (APP) metabolism in vivo and in vitro by genetic and pharmacologic approaches.

Results:

Here we show that overexpression of 12/15-LO leads to increased levels of β-secretase-1 (BACE1) mRNA and protein, a significant elevation in Aβ levels and deposition, and a worsening of memory deficits in AD transgenic mice. In vitro and in vivo studies demonstrate that 12/15-LO regulates BACE1 mRNA expression levels via the activation of the transcription factor Sp1. Thus, 12/15-LO–overexpressing mice had elevated levels of Sp1 and BACE1, whereas 12/15-LO–deficient mice had reduced levels of both. Preventing Sp1 activation by pharmacologic inhibition or dominant-negative mutant blocks the 12/15-LO–dependent elevation of Aβ and BACE1 levels.

Interpretation:

Our findings demonstrate a novel pathway by which 12/15-LO increases the amyloidogenic processing of APP through a Sp1-mediated transcriptional control of BACE1 levels that could have implications for AD pathogenesis and therapy. ANN NEUROL 2012;71:57–67

View Full Article (HTML) Get PDF (993K)